Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Rating of “Buy” by Brokerages

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have earned a consensus rating of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $63.67.

Several analysts recently issued reports on TARS shares. Oppenheimer lifted their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. HC Wainwright restated a “buy” rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Guggenheim restated a “buy” rating and set a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. Barclays cut their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Finally, Jefferies Financial Group raised their price target on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a report on Thursday, March 6th.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Crowley Wealth Management Inc. purchased a new position in shares of Tarsus Pharmaceuticals in the 4th quarter worth approximately $25,000. GF Fund Management CO. LTD. purchased a new position in shares of Tarsus Pharmaceuticals in the 4th quarter worth approximately $44,000. R Squared Ltd purchased a new position in shares of Tarsus Pharmaceuticals in the 4th quarter worth approximately $53,000. FMR LLC boosted its holdings in shares of Tarsus Pharmaceuticals by 236.6% in the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after purchasing an additional 3,537 shares during the period. Finally, Quarry LP bought a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $166,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Up 3.5 %

Shares of TARS opened at $48.09 on Friday. The business’s 50 day moving average is $49.11 and its 200 day moving average is $44.59. The company has a market capitalization of $1.85 billion, a PE ratio of -12.62 and a beta of 1.05. Tarsus Pharmaceuticals has a 12-month low of $20.08 and a 12-month high of $57.28. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.08. The company had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. Research analysts expect that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.